Immunomics

Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs

Retrieved on: 
Tuesday, September 6, 2022
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Clinical Trials, Cardiovascular disease, BTG, Becton, Dickinson and Company headquarters, Degenerative disease, C. R. Bard, Therapy, Boston Scientific, Vaccine, Regenerative medicine, Becton, ITI, LAMP, Infection, Senior, Intelligence, Neurology, Allergy, Immunomics, San Diego State University, Compliance, Leadership, FDA, Regulatory affairs, Company, Biotechnology, Allergan, History, Medtronic, Elective surgery, Lysosome-associated membrane glycoprotein, Pharmaceutical industry, Science, Biochemistry

Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs.

Key Points: 
  • Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs.
  • She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022.
  • I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison.
  • Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific).

Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma

Retrieved on: 
Wednesday, July 20, 2022
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Clinical Trials, Allergy, DNA, ITI, University of Washington School of Medicine, Antigen presentation, University, FIH, Merkel-cell carcinoma, Angela Merkel, History, Skin cancer, Immunomics, Infection, Therapy, Safety, DRS, Vaccine, MCC, Fred Hutchinson Cancer Research Center, Technology, Company, Plasmid, Patient, Infrared spectroscopy correlation table, Degenerative disease, Merkel cell polyomavirus, Lysosome-associated membrane glycoprotein, LAMP, Pharmaceutical industry

The eight-patient, open label, first-in-humans (FIH) study is designed to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with MCC who have undergone surgery.

Key Points: 
  • The eight-patient, open label, first-in-humans (FIH) study is designed to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with MCC who have undergone surgery.
  • We look forward to reporting top-line results from the Phase 1 trial in the second quarter of next year.
  • Additional information regarding the Phase 1 trial may be found at clinicaltrials.gov , using identifier: NCT05422781.
  • UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases.

Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2022

Retrieved on: 
Thursday, April 14, 2022
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Patent, Cancer, GBM, Glioblastoma, Survival, Brain, Immunomics, Patient, Infection, Congress, CMV, UNITE, Company, Vaccine, ITI, Antigen, Immune system, History, Degenerative disease, Neoplasm, LAMP, Allergy, Therapy, Pharmaceutical industry

Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that the company will be presenting at the World Vaccine Congress in Washington, DC being held April 18-21, 2022.

Key Points: 
  • Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that the company will be presenting at the World Vaccine Congress in Washington, DC being held April 18-21, 2022.
  • CEO and Founder Bill Hearl, Ph.D., will present a talk titled, Clinical Updates on Autologous Dendritic Cell Vaccines for Solid Tumors, at 10:10AM EDT on April 21, 2022.
  • Presentation details are as follows:
    ITI-1000 is an investigational dendritic cell vaccine therapy currently in a Phase 2 clinical trial (ATTAC-II) for the treatment of GBM.
  • ITI-1000 was developed using Immunomics proprietary investigational lysosomal targeting technology, UNITE, in the context of cell therapy.

Immunomic Therapeutics Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at the American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Clinical Trials, Therapy, Degenerative disease, Antigen presentation, UNITE, HER2, Vaccine, TAAS, Immunomics, Genome, Association, American Association for Cancer Research, Technology, APC, MCC, LAMP, CD8, MHC II, University, History, Trial of the century, Cancer, CD4, American Association, Immune system, MHC, CD40, CD154, Department, CD40L, ITI, Electroporation, DNA, LAMP1, Merkel cell polyomavirus, B cell, Survival, AACR, Poster, Doctor of Philosophy, Merkel-cell carcinoma, Allergy, Myelocyte, University of Washington, Patient, Company, Infection, Vaccination, Tumor microenvironment, Antigen, Neoplasm, Safety, Mouse, Pharmaceutical industry, MD, Medicine, Angela Merkel

The posters are accessible on the "Posters" section of Immunomic Therapeutics website at: https://www.immunomix.com/media/posters/ .

Key Points: 
  • The posters are accessible on the "Posters" section of Immunomic Therapeutics website at: https://www.immunomix.com/media/posters/ .
  • The majority of Merkel cell carcinomas (MCC), a rare and highly aggressive type of neuroendocrine skin cancer, are associated with Merkel cell polyomavirus (MCPyV) infection.
  • LTS220A, encoding a mutated form of MCPV-LT that diminishes its pro-oncogenic properties, was introduced into the UNITE platform.
  • We are highly encouraged by the data from the preclinical development for Her2-LAMP-sCD40L vaccine, stated Teri Heiland, PhD, Chief Scientific Officer of Immunomic Therapeutics.

Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the Treatment of Newly-Diagnosed Glioblastoma Patients

Retrieved on: 
Tuesday, November 30, 2021
Science, Other Science, Biotechnology, Research, Oncology, Health, Clinical Trials, Other Health, World Health Organization, ITI, Death, GBM, Company, Lysosome-associated membrane glycoprotein, Diagnosis, WHO, History, DNA, B cell, Biotechnology, Allergy, Infection, UNITE, Brain, Glioblastoma, World, Cancer, Acute myeloid leukemia, University, LAMP1, The Society of Neurological Surgeons, American Association of Neurological Surgeons, Duane Mitchell, Trial of the century, Degenerative disease, Partnership, American Brain Tumor Association, Human, Temozolomide, Vaccine, Survival, Adult, ATTAC, Therapy, American Association, Association, Patient, Duke University School of Medicine, LAMP, Duke University, Chemoradiotherapy, Antigen presentation, Astellas Pharma, Patent, Immunomics, RNA, Astrocyte, DC, CMV, Pharmaceutical industry, Glioblastoma (GBM), ITI-1000 and the Phase 2 (ATTAC-II) Study, UNITE, Immunomic Therapeutics, Inc., GLIOBLASTOMA (GBM), ITI-1000 AND THE PHASE 2 (ATTAC-II) STUDY, UNITE, IMMUNOMIC THERAPEUTICS, INC.

This is an extension of the Phase 2 ATTAC-II study ( NCT02465268 ) where eligibility is limited to those patients who have had surgery but have not yet received chemoradiation.

Key Points: 
  • This is an extension of the Phase 2 ATTAC-II study ( NCT02465268 ) where eligibility is limited to those patients who have had surgery but have not yet received chemoradiation.
  • ITIs dendritic cell vaccine is designed to target the pp65 viral antigen of Cytomegalovirus (CMV) that is expressed in GBM, but not in normal brain cells.
  • This dendritic cell vaccine is then returned to the patient.
  • The ATTAC-II study ( NCT02465268 ) is a Phase II randomized, placebo-controlled clinical trial enrolling patients with newly diagnosed GBM that will explore whether dendritic cell (DC) vaccines, including ITI-1000, targeting the CMV antigen pp65 improves survival.

Immunomic Therapeutics Presents Clinical Data From ATTAC Studies in GBM at the 2021 Society for Neurology (SNO) Annual Meeting

Retrieved on: 
Thursday, November 18, 2021
Research, Clinical Trials, Biotechnology, Health, University, Pharmaceutical, Science, Education, Oncology, Patient, Degenerative disease, Cancer, ITI, Company, Duke University School of Medicine, GBM, Lysosome-associated membrane glycoprotein, MD, Glioblastoma, LAMP, LTD, Acute myeloid leukemia, Human, University, Duke University, Vaccination, Vaccine, History, Annual general meeting, Survival, DNA, Phase, Patent, Biotechnology, Immunomics, SNO, RNA, Allergy, Infection, Therapy, Multimedia, The Society of Neurological Surgeons, UNITE, CMV, Pharmaceutical industry, ITI-1000 and the Phase 2 (ATTAC-II) Study, UNITE, Immunomic Therapeutics, Inc., ITI-1000 AND THE PHASE 2 (ATTAC-II) STUDY, UNITE, IMMUNOMIC THERAPEUTICS, INC.

The Phase II ATTAC study ( NCT00639639 ) led to an expanded cohort trial (ATTAC-GM: NCT00693639 ) resulting in positive immunologic and clinical response.

Key Points: 
  • The Phase II ATTAC study ( NCT00639639 ) led to an expanded cohort trial (ATTAC-GM: NCT00693639 ) resulting in positive immunologic and clinical response.
  • The larger confirmatory trial, ELEVATE ( NCT02366728 ), revealed significantly longer overall survival (OS) in patients randomized to LAMP pp65 RNA loaded DC vaccines combined with tetanus-diphtheria booster.
  • The results demonstrate that a CMV pp65-LAMP RNA-pulsed dendritic cell vaccination was associated with positive immunologic and clinical response in patients with glioblastoma (GBM).
  • ITI-1000 is an investigational dendritic cell vaccine therapy currently in a Phase 2 clinical trial (ATTAC-II) for the treatment of GBM.

Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme Disease

Retrieved on: 
Saturday, October 2, 2021
Blood, Infection, PCR, PPA, Diagnosis, Immunity, Patient, Microsoft, Virus, Immune system, Biology, NPA, COVID, Lyme disease, Antibody, General manager, RT, Disease, Genetics, ADPT, TCR, COVID-19, Technology, Severe acute respiratory syndrome coronavirus 2, Data, Immunomics, Count key data, GLOBE, Vaccine, Pharmaceutical industry, Heating, ventilation, and air conditioning

SEATTLE, Oct. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, is presenting new data from three studies demonstrating the potential clinical utility of T-cell testing using T-cell receptor (TCR) repertoire characterization for infectious diseases during IDWeek 2021, which is being held virtually. Data demonstrate potential advantages over conventional testing methods in SARS-CoV-2 and Lyme disease.

Key Points: 
  • In SARS-CoV-2, new real-world data demonstrate that T-Detect COVID can detect prior infection nearly 12 months after diagnosis in some patients.
  • Additionally, T-cell testing can be used to distinguish natural SARS-CoV-2 infection from COVID-19 vaccine response, an important advantage over antibody tests.
  • These data play a critical role in advancing the T-Detect pipeline and Adaptives vision to leverage data from the human immune system to diagnose and treat disease.
  • T-cell testing using TCR repertoire characterization can provide a consistent and trackable measure of the immune response to many diseases, such as SARS-CoV-2 and Lyme disease.

ImmunoScape Expands its Executive and Scientific Teams to Extend Use of its Deep Immunomics Platform into Drug Discovery

Retrieved on: 
Tuesday, June 29, 2021
Health, Genetics, Other Science, General Health, Research, Science, Biotechnology, Surnames, Immunology, Immunomics, MacLeod

The new hires include Dr. Dan MacLeod, Vice President of Discovery, Dr. Katja Fink, Senior Director, Hit Discovery Program, and Dr. Andreas Wilm, Director of Computational Biology.

Key Points: 
  • The new hires include Dr. Dan MacLeod, Vice President of Discovery, Dr. Katja Fink, Senior Director, Hit Discovery Program, and Dr. Andreas Wilm, Director of Computational Biology.
  • (Photo: Business Wire)
    As the Vice President of Discovery at ImmunoScape based out of San Diego, Dr. Dan MacLeod will spearhead ImmunoScapes push into the drug discovery space.
  • Dr. MacLeod brings over 15 years of education and experience across immunology, oncology, cancer, immunotherapy, gene-editing, and virology to ImmunoScape.
  • ImmunoScapes Deep Immunomics platform is able to deliver unprecedented insights into the human immune system, which is critical in advancing the development and commercialization of novel therapies in drug discovery programs, said Dr. MacLeod, VP of Discovery at ImmunoScape.

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in the UK COVID-19 Human Challenge Study to Investigate the T Cell Response to SARS-CoV-2 Infection

Retrieved on: 
Tuesday, May 18, 2021
Tuberculosis, Medical specialties, Medicine, Health, T-SPOT.TB, COVID-19 testing, Immune system, COVID-19, Vaccine, ELISPOT, Tuberculosis diagnosis, Immunomics

The kit uses the T-SPOT technology platform, a standardized ELISPOT methodology, to detect the T cell immune response in study subjects.

Key Points: 
  • The kit uses the T-SPOT technology platform, a standardized ELISPOT methodology, to detect the T cell immune response in study subjects.
  • Understanding the T cell immune response, in addition to the antibody response (via serology), may offer additional insights into how the complete immune system responds to infection and vaccination.
  • Our leading product, the T-SPOT.TB test, is used for diagnosing infection with Tuberculosis, the world\xe2\x80\x99s largest cause of death from infectious disease.
  • The recently released T-SPOT.COVID test is CE marked in Europe for clinical use to detect the T cell immune response to SARS-CoV-2 ( www.tspotcovid.com ).

ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery

Retrieved on: 
Wednesday, April 14, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Immunomics, Flow cytometry, Immunome, Bioinformatics, Cytometry Part A, ImmunoScape, Anzu Partners, EDBI, UTEC

The company will also be able to continue advancing the capabilities of its Deep Immunomics platform that enables the characterization of a patient\xe2\x80\x99s immunome at ultra-high resolution.

Key Points: 
  • The company will also be able to continue advancing the capabilities of its Deep Immunomics platform that enables the characterization of a patient\xe2\x80\x99s immunome at ultra-high resolution.
  • This new financing will allow us deepen our relationships with partners in the development of next generation therapeutics.\xe2\x80\x9d\nImmunoScape\xe2\x80\x99s Deep Immunomics platform integrates single-cell analysis technologies and cutting-edge bioinformatics for both drug discovery and high-dimensional immune profiling.
  • The company's Deep Immunomics platform combines mass cytometry, single cell sequencing, and proprietary computational bioinformatics, data analysis, and visualization tools to provide novel, reproducible immune profiling information.
  • As a value creating investor, EDBI assists companies achieve their ambitious goals by leveraging our broad network, resources and expertise.